| Dr Jaime L Go, MD | |
|
6315 Pearl Rd, Ste 206, Parma Heights, OH 44130-3082 | |
| (440) 884-2126 | |
| (440) 884-2127 |
| Full Name | Dr Jaime L Go |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Location | 6315 Pearl Rd, Parma Heights, Ohio |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548257850 | NPI | - | NPPES |
| 0652600 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 47885 (Ohio) | Primary |
| Entity Name | North East Ohio Group Practice Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063575462 PECOS PAC ID: 8426960618 Enrollment ID: O20031105000352 |
News Archive
A new study has revealed the underlying mechanism of development of antibiotic resistance among Pseudomonas aeruginosa (P. aeruginosa). Pseudomonas is known to cause severe and often life threatening infections in humans. These infections become further difficult to treat because of the development of resistance against commonly used antibiotics.
Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.
In a survey-based study published in the International Journal of Dermatology, having tattoos was not significantly related to overall health status, but individuals with tattoos were more likely to be diagnosed with a mental health issue and to report sleep problems.
Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, is pleased to announce it has signed a worldwide non-exclusive licensing agreement with the National Institutes of Health ('NIH'), a division of the U.S. Department of Health and Human Services, for use of the melanoma antigens TRP-2 and gp100, key components of Scancell's lead ImmunoBody® vaccine for melanoma, SCIB1.
› Verified 6 days ago
| Entity Name | Cleveland Clinic Health System - East Region |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235183542 PECOS PAC ID: 2264337955 Enrollment ID: O20031205000028 |
News Archive
A new study has revealed the underlying mechanism of development of antibiotic resistance among Pseudomonas aeruginosa (P. aeruginosa). Pseudomonas is known to cause severe and often life threatening infections in humans. These infections become further difficult to treat because of the development of resistance against commonly used antibiotics.
Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.
In a survey-based study published in the International Journal of Dermatology, having tattoos was not significantly related to overall health status, but individuals with tattoos were more likely to be diagnosed with a mental health issue and to report sleep problems.
Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, is pleased to announce it has signed a worldwide non-exclusive licensing agreement with the National Institutes of Health ('NIH'), a division of the U.S. Department of Health and Human Services, for use of the melanoma antigens TRP-2 and gp100, key components of Scancell's lead ImmunoBody® vaccine for melanoma, SCIB1.
› Verified 6 days ago
| Entity Name | Marymount Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720031131 PECOS PAC ID: 6507763661 Enrollment ID: O20031217000026 |
News Archive
A new study has revealed the underlying mechanism of development of antibiotic resistance among Pseudomonas aeruginosa (P. aeruginosa). Pseudomonas is known to cause severe and often life threatening infections in humans. These infections become further difficult to treat because of the development of resistance against commonly used antibiotics.
Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.
In a survey-based study published in the International Journal of Dermatology, having tattoos was not significantly related to overall health status, but individuals with tattoos were more likely to be diagnosed with a mental health issue and to report sleep problems.
Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, is pleased to announce it has signed a worldwide non-exclusive licensing agreement with the National Institutes of Health ('NIH'), a division of the U.S. Department of Health and Human Services, for use of the melanoma antigens TRP-2 and gp100, key components of Scancell's lead ImmunoBody® vaccine for melanoma, SCIB1.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jaime L Go, MD 1434 Homestead Creek Dr, Broadview Hts, OH 44147-2582 Ph: (440) 884-2126 | Dr Jaime L Go, MD 6315 Pearl Rd, Ste 206, Parma Heights, OH 44130-3082 Ph: (440) 884-2126 |
News Archive
A new study has revealed the underlying mechanism of development of antibiotic resistance among Pseudomonas aeruginosa (P. aeruginosa). Pseudomonas is known to cause severe and often life threatening infections in humans. These infections become further difficult to treat because of the development of resistance against commonly used antibiotics.
Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.
In a survey-based study published in the International Journal of Dermatology, having tattoos was not significantly related to overall health status, but individuals with tattoos were more likely to be diagnosed with a mental health issue and to report sleep problems.
Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, is pleased to announce it has signed a worldwide non-exclusive licensing agreement with the National Institutes of Health ('NIH'), a division of the U.S. Department of Health and Human Services, for use of the melanoma antigens TRP-2 and gp100, key components of Scancell's lead ImmunoBody® vaccine for melanoma, SCIB1.
› Verified 6 days ago
Muyuan Ma, MD General Practice Medicare: Medicare Enrolled Practice Location: 7022 Brandywine Rd, Parma Heights, OH 44130 Phone: 614-704-2717 |